12 completed, 1 withdrawn. 13 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 12, Withdrawn 1 |
| Phase 3 | 3 | Completed 3 |
Follow glimepiride: new trials by email Literature Review of glimepiride trials Research Report on glimepiride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus JTT-851, Glimepiride, Placebo for Active - Type 2 Diabetes Mellitus | Phase 2 | Completed | Akros Pharma Inc. | 325 | 2012-09-01 | 2013-08-01 |
| The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY) liraglutide, Glimepiride - Maturity-onset Diabetes of the Young | Phase 2 / Phase 3 | Completed | University Hospital, Gentofte, Copenhagen | 15 | 2012-08-01 | 2013-09-05 |
| Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin Placebo, PF-04937319 10 mg, PF-04937319 50 mg - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Pfizer | 304 | 2012-02-01 | 2017-01-31 |
| Liraglutide and Heart Failure in Type 2 Diabetes liraglutide, glimepiride, Metformin - Congestive Heart Failure, Type 2 Diabetes Mellitus | Phase 2 | Completed | Thomas Nystrom | 62 | 2012-01-01 | 2016-09-01 |
| A Study in Patients With Type 2 Diabetes LY2608204, Glimepiride - Diabetes Mellitus, Type 2 | Phase 2 | Withdrawn | Eli Lilly and Company | 240 | 2011-09-01 | 2011-08-25 |
| To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies Canakinumab 150 mg, Placebo to Canakinumab - Type 2 Diabetes Mellitus, Impaired Glucose Tolerance | Phase 2 | Completed | Novartis | 246 | 2010-02-01 | 2011-09-05 |
| Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus TAK-875, Glimepiride, Placebo - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Takeda | 426 | 2009-12-01 | 2016-04-13 |
| Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan Alogliptin and glimepiride, Alogliptin and metformin - Type 2 Diabetes Mellitus | Phase 2 / Phase 3 | Completed | Takeda | 576 | 2009-01-01 | 2012-08-16 |
| A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017) MK-0941, Glimepiride, Metformin - Type 2 Diabetes Mellitus | Phase 2 | Completed | Merck Sharp & Dohme LLC | 143 | 2009-01-01 | 2015-12-17 |
| Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan Alogliptin and glimepiride, Glimepiride - Type 2 Diabetes Mellitus | Phase 2 / Phase 3 | Completed | Takeda | 312 | 2008-08-01 | 2012-02-03 |
| Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes Linagliptin, Placebo, Glimepiride - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Boehringer Ingelheim | 333 | 2006-04-01 | 2014-07-08 |
| Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes liraglutide, metformin, placebo - Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Novo Nordisk A/S | 145 | 2002-08-01 | 2017-01-25 |
| Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes placebo, liraglutide, glimepiride - Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Novo Nordisk A/S | 196 | 2000-10-01 | 2017-01-24 |
Diabetes Mellitus, Type 2 (13) · Diabetes Mellitus (6) · Glucose Intolerance (1) · Heart Failure (1) · Mason-Type Diabetes (1) · Maturity-Onset Diabetes of the Young, Type 3 (1) · Metabolic Syndrome (1)
Takeda (3) · Novo Nordisk A/S (2) · Akros Pharma Inc. (1) · Boehringer Ingelheim (1) · Eli Lilly and Company (1) · Merck Sharp & Dohme LLC (1) · Novartis (1) · Pfizer (1) · Thomas Nystrom (1) · University Hospital, Gentofte, Copenhagen (1)
United States (5) · Germany (4) · Denmark (3) · Sweden (3) · United Kingdom (3) · Australia (2) · Austria (2) · Canada (2) · Czechia (2) · France (2) · India (2) · Poland (2) · Slovakia (2) · Bulgaria (1) · Finland (1)
Hisashi Kodama, Ph.D. (1) · Johan Jendle, MD, PhD (1)
PMID 24843617, PMID 25504028, PMID 15161785, PMID 17039422, PMID 22374408, PMID 24929431, PMID 25885172, PMID 29548934, PMID 34920733, PMID 37349083
2005 (1)